Charles Glabe

Active 1977–2024

116
Papers
35,320
Citations
93
h-index
116
i10-index

Citations

Citations per year for Charles Glabe1977: 2 citations1978: 3 citations1979: 4 citations1980: 3 citations1981: 2 citations1982: 5 citations1983: 5 citations1984: 3 citations1985: 3 citations1986: 6 citations1987: 10 citations1989: 3 citations1990: 7 citations1991: 17 citations1992: 35 citations1993: 63 citations1994: 65 citations1995: 66 citations1996: 59 citations1997: 98 citations1998: 109 citations1999: 102 citations2000: 123 citations2001: 118 citations2002: 157 citations2003: 151 citations2004: 229 citations2005: 272 citations2006: 460 citations2007: 631 citations2008: 666 citations2009: 714 citations2010: 777 citations2011: 777 citations2012: 779 citations2013: 596 citations2014: 607 citations2015: 561 citations2016: 474 citations2017: 494 citations2018: 428 citations2019: 1,026 citations2020: 1,070 citations2021: 877 citations2022: 648 citations2023: 472 citations2024: 653 citations2025: 264 citations2026: 8 citations1988: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,647 citing papers, 31.8% of this breakdownChina: 1,034 citing papers, 7.1% of this breakdownUnited Kingdom: 921 citing papers, 6.3% of this breakdownGermany: 804 citing papers, 5.5% of this breakdownItaly: 617 citing papers, 4.2% of this breakdownJapan: 527 citing papers, 3.6% of this breakdownIndia: 500 citing papers, 3.4% of this breakdownCanada: 467 citing papers, 3.2% of this breakdownAustralia: 416 citing papers, 2.9% of this breakdownFrance: 416 citing papers, 2.8% of this breakdownSweden: 345 citing papers, 2.4% of this breakdownSpain: 319 citing papers, 2.2% of this breakdown
0%31.8%Other 24.6%

Fields

  • Medicine64.7%
  • Biochemistry, Genetics and Molecular Biology19%
  • Neuroscience8.7%
  • Immunology and Microbiology1.5%
  • Materials Science1.4%
  • Chemistry1.1%
  • Other3.6%

Topics

  • Alzheimer's disease research and treatments21.8%
  • Cholinesterase and Neurodegenerative Diseases4.9%
  • Computational Drug Discovery Methods4.6%
  • Neuroinflammation and Neurodegeneration Mechanisms4.1%
  • Prion Diseases and Protein Misfolding3.1%
  • Protein Structure and Dynamics2.9%
  • Other58.6%

Coauthors

All papers

Open in search
  1. Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo

    Authors: , , , , , , , , , , - Journal of Biological Chemistry 2004 cited by 2,306

  2. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

    Authors: , , , , , , - Science 2003 cited by 4,088

  3. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease

    Authors: , , , , , , - Molecular Neurodegeneration 2018 cited by 410

  4. A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Neuroscience 2013 cited by 546

  5. Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril

    Authors: , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 822

  6. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers

    Authors: , , , , , , , , , , , , , - Molecular Neurodegeneration 2007 cited by 782

  7. RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory

    Authors: , , , , , , , - Nature 2006 cited by 2,758

  8. Accumulation of Toxic α-Synuclein Oligomer within Endoplasmic Reticulum Occurs in α-SynucleinopathyIn Vivo

    Authors: , , , , , - Journal of Neuroscience 2012 cited by 328

  9. Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease

    Authors: , , , , , , , , , , , - Alzheimer s & Dementia 2022 cited by 74

  10. Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2023 cited by 47

  11. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology

    Authors: , , , , , , , , , , , , , - Acta Neuropathologica 2017 cited by 128

  12. Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦

    Authors: , , , , , - Journal of Biological Chemistry 2005 cited by 1,030

  13. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β

    Authors: , , , , , , , , , , , , , , , , , - Nature 2012 cited by 429

  14. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid

    Authors: , , , , , - Journal of Neuroinflammation 2008 cited by 242

  15. Structure-based inhibitors of amyloid beta core suggest a common interface with tau

    Authors: , , , , , , , , , , , , , - eLife 2019 cited by 116

  16. Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases

    Authors: , , , , , , , , , , , , - American Journal Of Pathology 2015 cited by 110

  17. Inefficient quality control of ribosome stalling during APP synthesis generates CAT-tailed species that precipitate hallmarks of Alzheimer’s disease

    Authors: , , , , , , , , , , , , , - Acta Neuropathologica Communications 2021 cited by 64

  18. Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases

    Authors: , , , , , , - Journal of Biological Chemistry 2004 cited by 904

  19. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia

    Authors: , , , , , , , , - Science Translational Medicine 2014 cited by 482

  20. Progressive accumulation of amyloid‐β oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins

    Authors: , , , , , , , , , , , , - FEBS Journal 2010 cited by 218

  21. Familial Alzheimer’s Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β Peptide

    Authors: , , , - Journal of Biological Chemistry 2017 cited by 150

  22. Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques

    Authors: , , , , , , , , , , , - Neurobiology of Disease 2014 cited by 128

  23. Epitomic Characterization of the Specificity of the Anti-Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8

    Authors: , , , , - Journal of Alzheimer s Disease 2018 cited by 94

  24. Autophagy defends pancreatic β cells from human islet amyloid polypeptide-induced toxicity

    Authors: , , , , - Journal of Clinical Investigation 2014 cited by 205